18+ Adults only. We do not sell to anyone under 18. Research compounds are supplied for research use only.
Five rising bars that level off, a picture of weight loss rising with dose and then plateauing

GLP-1 dosing: what the research says about dose and weight loss

“What dose?” is one of the most common questions about GLP-1 compounds, and it is the one the trial papers answer most carefully. This guide does not tell anyone what to take. It sets out what the published trials found when different doses were compared, what a dose actually means in those studies, and where more stops being better.

GLP-1 dose and weight loss in 60 seconds

  • In dose-ranging trials, higher doses produced more weight loss, up to a point, and then the curve flattened.
  • Tirzepatide at 5, 10 and 15 mg produced average losses of 15.0, 19.5 and 20.9 percent over 72 weeks, against 3.1 percent on placebo.
  • Gut side effects were more common at higher doses and clustered around dose increases.
  • The trial doses were reached by stepping up slowly. They were never the starting dose.

What a “dose” means in a trial

When a paper says a trial used 2.4 mg of semaglutide or 15 mg of tirzepatide, that is the maintenance dose, the level people were stepped up to. Participants started much lower and climbed over weeks. In SURMOUNT-1, the tirzepatide trial, the dose-escalation period alone lasted 20 weeks of a 72 week study. So a trial dose describes where people ended up, not where anyone began. Our guide to why GLP-1 doses start low covers the escalation side in detail.

Semaglutide: the phase 2 dose-ranging trial

The cleanest look at dose and response for semaglutide comes from a phase 2 trial in 957 adults with obesity and no diabetes. People received one of five once-daily semaglutide doses (0.05, 0.1, 0.2, 0.3 or 0.4 mg), liraglutide 3.0 mg, or placebo, with diet and activity advice. Each dose was reached by stepping up every four weeks. At week 52 the average weight change was:

Two things stand out. First, there was a clear step up from the lowest doses to 0.2 mg. Second, the curve was not a straight line: the 0.3 mg group lost slightly less on average (11.2 percent) than the 0.2 mg group (11.6 percent), and the best average result came at 0.4 mg. Each dose group held only about 100 people, so a small gap between neighbouring doses, like 0.2 and 0.3 mg here, should not be over-read. The authors also reported that the most common adverse events were gut symptoms, mainly nausea, and that they were dose related.

Tirzepatide: three doses, one trial

SURMOUNT-1 compared three weekly tirzepatide doses against placebo in 2,539 adults with obesity, or overweight plus a weight-related condition, and without diabetes. At 72 weeks the average weight change was -15.0 percent at 5 mg, -19.5 percent at 10 mg and -20.9 percent at 15 mg, against -3.1 percent on placebo. Going from 5 mg to 10 mg added about 4.5 percentage points on average. Going from 10 mg to 15 mg added about 1.4 more. That is the same shape as the semaglutide data: a big gain early, then smaller returns.

The price of a higher dose

The same trial reported that the most common adverse events were gut related, mostly mild to moderate, and that they occurred mainly during dose escalation. Adverse events led to people stopping treatment in 4.3 percent at 5 mg, 7.1 percent at 10 mg and 6.2 percent at 15 mg, compared with 2.6 percent on placebo. The semaglutide STEP 2 trial, in adults with type 2 diabetes, showed a similar pattern at two doses: gut adverse events were reported by 63.5 percent on 2.4 mg and 57.5 percent on 1.0 mg, compared with 34.3 percent on placebo.

In plain terms, a higher dose bought more average weight loss and also more gut side effects. How that trade-off sits for any one person is a clinical judgement, which is why these medicines are titrated under a doctor’s supervision.

Why the averages hide a lot

An average is not a promise. In STEP 1, where the average loss on semaglutide 2.4 mg was 14.9 percent over 68 weeks, 86.4 percent of participants lost at least 5 percent of their body weight, 69.1 percent lost at least 10 percent and 50.5 percent lost at least 15 percent. Put another way, about half did not reach 15 percent, even at the full trial dose. And on the other side, 4.5 percent stopped semaglutide because of gut events, against 0.8 percent on placebo.

The population matters as well. STEP 2 enrolled adults with type 2 diabetes, and their average loss on 2.4 mg was 9.6 percent, well below the 14.9 percent in STEP 1, which excluded diabetes. The dose was identical. The result was not. So a dose from one trial does not translate to everyone, and the result you read about may not describe the group you belong to.

What these trials cannot tell you

  • The right dose for an individual. The trials report group averages, not what a particular person should take.
  • Whether a research-grade vial matches the label. The trials used pharmaceutical products of known strength. Our guide to the certificate of analysis explains what to ask a supplier for.
  • Whether doses can be compared across compounds. A milligram of tirzepatide and a milligram of semaglutide are different molecules with different potency, so numbers between them cannot be lined up.
  • Long-term outcomes at each dose. The trials above ran 52 to 72 weeks.

Where this leaves you in South Africa

Semaglutide and tirzepatide sold under brand names are prescription medicines, and a doctor sets the dose. The compounds we supply are sold for research use only and are not registered medicines, so none of the trial doses above is a recommendation. If you work with a vial, measuring it correctly is its own skill: see how to reconstitute a peptide vial and pens versus vials. For the molecules themselves, see semaglutide and tirzepatide.

Questions people ask

Does a higher GLP-1 dose cause more weight loss?

On average, up to a point. In the tirzepatide trial, 5, 10 and 15 mg produced average losses of 15.0, 19.5 and 20.9 percent. The gain shrank as the dose rose, and side effects were more common at higher doses.

What dose of semaglutide was used in the weight loss trials?

The main STEP 1 trial used 2.4 mg once a week, reached by stepping up from a much lower starting dose. An earlier phase 2 trial tested once-daily doses from 0.05 to 0.4 mg. These are trial doses, not recommendations.

Is the highest dose always the best one?

Not necessarily. Returns diminish at higher doses, and gut side effects and stopping rates were higher at 10 and 15 mg of tirzepatide than at 5 mg. The choice is a clinical judgement.

Why did people in the trials not start on the full dose?

Gut side effects occurred mainly during dose escalation, so doses were raised in steps over weeks to months. See our guide on why GLP-1 doses start low.

Do trial results apply to people with type 2 diabetes?

Not directly. In STEP 2, adults with type 2 diabetes lost an average of 9.6 percent on semaglutide 2.4 mg, compared with 14.9 percent in STEP 1, which excluded diabetes.

Sources

  1. O’Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018;392:637-649.
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216.
  3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
  4. Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971-984.

This article is for educational purposes only and is not medical advice. The compounds we supply are sold for research use only and are not registered medicines. Our guide to whether peptides are legal in South Africa explains what that means.

Next, read slimming injections in South Africa or compare the molecules in retatrutide vs tirzepatide vs semaglutide.